News

Viral Safety Expert, Audrey Brussel, joins PathoQuest
Viral Safety Expert, Audrey Brussel, joins PathoQuest

PathoQuest announces the appointment of Audrey Brussel, Ph.D. to the newly created position of Viral Safety Leader. Her addition to the company will strengthen PathoQuest’s in-house expertise in viral safety. Her insights and knowledge of the pharmaceutical industry from a customer’s perspective will help deliver a better service and support the growth of the company’s rapidly expanding quality control testing business for biologics.

read more
Transgene chooses PathoQuest innovative NGS-based safety release test for TG4050 phase I clinical trial targeting patients with head-neck and ovarian cancers and for Invir.IO™ a platform for recombinant viral vector manufacturing.
Transgene chooses PathoQuest innovative NGS-based safety release test for TG4050 phase I clinical trial targeting patients with head-neck and ovarian cancers and for Invir.IO™ a platform for recombinant viral vector manufacturing.

Transgene is a French biotechnology company focused on designing and developing next generation immunotherapeutics. In these phase 1 trials with 85 patients, Transgene has chosen PathoQuest next generation sequencing (NGS) solutions for its fast and cost-effective viral safety testing approach of the product. 

read more

Click here to learn more about PathoQuest’s Biologics Genomic Service for biopharmaceutical companies.

Connect